مقدمة
Retinal degeneration and corneal opacities represent some of the most devastating conditions in paediatric ophthalmology. For children affected by these conditions, conventional medicine has historically offered limited options — with many facing lifelong visual impairment or blindness. BCRMED’s ACE Retino™ clinical trial represents a significant step toward changing that reality.
About the ACE Retino™ Trial
The ACE Retino™ clinical trial (registered as NCT06787482 on ClinicalTrials.gov) is investigating the safety, tolerability, and preliminary efficacy of ACE Retino™ — a Pico Cell Matrix-derived formulation — in paediatric patients with corneal opacity and associated retinal and/or optic nerve involvement. This is the first in-human investigation of ACE Retino™ in a paediatric ocular pathology setting.
The Technology: Pico Cell Matrix
ACE Retino™ is produced through BCRMED’s proprietary Pico Cell Matrix technology, which processes tissue-derived peptides into nanometer and picometer-scale bioactive particles. This process preserves a rich profile of retinal-specific growth factors, exosomal signals, neuroprotective peptides, and organotropic complexes that support the eye’s natural regenerative capacity. The ultra-small particle size is key — it enables these bioactive molecules to reach ocular tissues that are otherwise difficult to penetrate.
Why This Trial Matters
Retinal degenerative diseases represent a major cause of irreversible vision impairment globally. Current clinical evidence shows that stem cell and regenerative approaches for retinal conditions have transitioned from preclinical investigation into early-phase trials with promising safety profiles. ACE Retino™ offers a novel, non-surgical adjunctive pathway — potentially reducing the lifetime visual disability burden for affected children without requiring invasive procedures.
What the Trial Is Measuring
The primary outcome measures include safety endpoints — adverse events and tolerability — alongside vision and retinal function parameters such as visual acuity, retinal imaging, and electrophysiology. Participants undergo serial assessments of ocular structure and function throughout the defined study period. The trial is conducted under Good Clinical Practice standards with full ethical oversight.
Who Can Participate
The trial is open to children with documented corneal opacity and retinal or optic nerve involvement who meet the inclusion and exclusion criteria defined in the trial protocol. Parents and legal guardians are encouraged to review the full informed consent documentation on ClinicalTrials.gov (NCT06787482) or contact the BCRMED clinical team directly for further information.
An Important Disclosure
ACE Retino™ is currently under clinical investigation and is not yet approved for general treatment of retinal or corneal conditions. All participants and their guardians should carefully review the risks, benefits, and alternatives outlined in the consent documentation. The trial status may change; always refer to the clinical registry for the most current information.
Conclusion
The ACE Retino™ trial reflects BCRMED’s commitment to rigorous, evidence-based advancement in regenerative ophthalmology. We believe that the children who cannot yet be helped by conventional medicine deserve access to the most promising emerging therapies — evaluated with full scientific and ethical rigour.
Call to Action: Read the full trial details at bcregmed.co.uk/ace-retino-clinical-trial or visit ClinicalTrials.gov: NCT06787482